Bringing Precision Medicine to Cholangiocarcinoma With Mitesh Borad, MD

STATEMENT OF NEED

With an estimated incidence of 8,000 new cases per year, cholangiocarcinoma is a rare and aggressive tumor type that accounts for only 3% of all gastrointestinal cancers. Outcomes are poor, with 5-year survival rates ranging from 24% to as low as 2%. In this episode of Oncology Data Advisor, Mitesh J. Borad, MD, Associate Professor of Medicine and Director of the Liver and Biliary Cancer Research Program at the Mayo Clinic Cancer Center in Phoenix, Arizona, joins i3 Health for a discussion that covers the efficacy and adverse events of FGFR inhibitor therapy, ongoing research related to additional therapeutic targets, and the increasing role of precision medicine in the treatment of patients with cholangiocarcinoma.

TARGET AUDIENCE

Medical oncologists and other health care professionals involved in the treatment of cholangiocarcinoma

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

1.) Account for tumor genomic factors when determining treatment for patients with cholangiocarcinoma
2.) Identify and manage toxicities from FGFR inhibitor therapy in patients with cholangiocarcinoma